CD19: a biomarker for B cell development, lymphoma diagnosis …
2012年11月29日 · CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling.
CD19 - Lab Results explained | HealthMatters.io
The CD19 antigen (aka B-lymphocyte antigen CD19 or Cluster of Differentiation 19) plays an important role in clinical oncology. It’s a protein found on the surface of B-cells, a type of white blood cell. Since CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell ...
CD19 - an overview | ScienceDirect Topics
CD19 is a 95 kDa transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is expressed on B cells throughout most stages of B-cell differentiation. It forms a signal transduction complex and is commonly found in B cell–derived malignancies and …
CD19 Gene - GeneCards | CD19 Protein | CD19 Antibody
2024年10月1日 · CD19 (CD19 Molecule) is a Protein Coding gene. Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are Constitutive Signaling by Aberrant PI3K in Cancer and PIP3 activates AKT signaling.
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case …
2024年2月21日 · CD19 CAR T-cell therapy was effective independent of previous B-cell targeting by monoclonal antibodies.
CD19 is essential for B cell activation by promoting B cell receptor ...
2007年12月2日 · CD19 regulates the threshold of B cell activation 9,10, and thus we were interested in defining the role of CD19 in the absence of co-ligation to BCR. As we had established that BCR-antigen ...
Safety, efficacy and determinants of response of allogeneic CD19 ...
2024年1月18日 · We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell...
CD19 as an attractive target for antibody-based therapy - PMC
CD19 is a pan-B cell marker that is recognized as a potential immunotherapy target for B cell disorders, including blood-borne malignancies and autoimmune diseases. Although initial attempts to target CD19 were unsuccessful, a new wave …
CD19 - an overview | ScienceDirect Topics
CD19 is a transmembrane glycoprotein member of the immunoglobulin superfamily. It consists of a single transmembrane domain, cytoplasmic C-terminus, and extracellular N-terminus. CD19 lacks structural homology with any known human proteins. CD19 is present on the surface of B-cells and is considered B-cell specific [3]. CD19 expression occurs ...
Modulation of CD19 surface expression in B cell acute ... - Nature
2022年9月23日 · Immunotherapeutic targeting of the surface glycoprotein CD19 has markedly improved outcomes in patients with relapsed and refractory B cell progenitor acute lymphoblastic leukemia.
- 某些结果已被删除一些您可能无法访问的结果已被隐去。显示无法访问的结果